
COVID-19 vaccination is key to restoring early-phase anticancer drug development
Vaccination among cancer patients should not affect their participation in clinical trials and levels of acceptance of the vaccine are high
Vaccination among cancer patients should not affect their participation in clinical trials and levels of acceptance of the vaccine are high
Over the last decade, much progress has been made in developing a range of antibody–drug conjugates to treat breast cancer, with the construction of bespoke agents for individual patients and exciting prospect for the future
This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.
For more detailed information on the cookies we use, please check our Privacy Policy.
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.